title: [Cure rates of chronic subclinical Staphylococcus aureus mastitis in lactating dairy cows after antibiotic therapy].
abstract: Staphylococcus (S.) aureus is an important mastitis causing pathogen in dairy cows worldwide. The aim of this controlled and randomized study was to analyze the effects of an antibiotic treatment on chronic subclinical S.aureus mastitis during lactation.The study was conducted between July 2011 and December 2011 in Northern Germany including 134 udder quarters (i. e. 103 dairy cows) infected with S. aureus. The animals were randomly divided into two groups (control and treatment group). Quarter foremilk duplicate samples were taken on days 0, 7, 32 and 39 from each infected udder quarter for microbiological analysis and somatic cell count determination. Treatment consisted of cephalexin (200 mg intramammarily 5 times every 12 h) plus marbofloxacine (2 mg/kg BM subcutaneously 3 times every 24 h). "Pathogen elimination" was assessed as the status, when no S. aureus was isolated from the quarter samples of days 32 and 39. "Cure" was defined as the status, when in addition to pathogen elimination the somatic cell count of the quarter in both milk samples was below 100 000/ml. Animals of the treatment group showed a pathogen elimination rate of 35.9% and a cure rate of 21.9%. The rates for the control group were 21.4% and 8.6%, resp. The differences between groups were statistically significant. These results indicate that pathogen elimination and cure rates of chronic subclinical S. aureus mastitis are low after an intramammary cephalexin and subcutaneous marbofloxacine treatment, but still significantly better than without any antibiotic treatment.
authors.affiliation: Landesamt für Verbraucherschutz Sachsen-Anhalt, Stendal.
authors.forename: Miriam
authors.initials: M
authors.lastname: Linder
authors.forename: Jan-Hendrik
authors.initials: JH
authors.lastname: Paduch
authors.forename: Anne-Sophie
authors.initials: AS
authors.lastname: Grieger
authors.forename: Ellen
authors.initials: E
authors.lastname: Mansion-de Vries
authors.forename: Nicole
authors.initials: N
authors.lastname: Knorr
authors.forename: Claudia
authors.initials: C
authors.lastname: Zinke
authors.forename: Klaus
authors.initials: K
authors.lastname: Teich
authors.forename: Volker
authors.initials: V
authors.lastname: Krömker
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D002417:Cattle; D002506:Cephalexin / Q000008:administration & dosage*; D002908:Chronic Disease; D004359:Drug Therapy, Combination / Q000662:veterinary; D005260:Female; D024841:Fluoroquinolones / Q000008:administration & dosage*; D007775:Lactation Disorders / Q000188:drug therapy / Q000662:veterinary*; D008414:Mastitis, Bovine / Q000188:drug therapy*; D008892:Milk / Q000382:microbiology; D013203:Staphylococcal Infections / Q000188:drug therapy / Q000662:veterinary*; D013211:Staphylococcus aureus / Q000187:drug effects / Q000302:isolation & purification; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; C080260:marbofloxacin; D002506:Cephalexin